Cargando…

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder

AIMS: When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended‐release (viloxazine ER) using measures of effect s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasser, Azmi, Kosheleff, Alisa R., Hull, Joseph T., Liranso, Tesfaye, Qin, Peibing, Busse, Gregory D., Fava, Maurizio, Maletic, Vladimir, Rubin, Jonathan, Lopez, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365735/ https://www.ncbi.nlm.nih.gov/pubmed/33971070 http://dx.doi.org/10.1111/ijcp.14330

Ejemplares similares

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials
por: Nasser, Azmi, et al.
Publicado: (2021)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults
por: Wang, Zhao, et al.
Publicado: (2021)

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree(TM)) in Healthy Adult Subjects
por: Wang, Zhao, et al.
Publicado: (2021)

Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
por: Nasser, Azmi, et al.
Publicado: (2022)

The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2021)

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
por: Faraone, Stephen V., et al.
Publicado: (2021)

Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree(®)): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2023)

Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
por: Johnson, Janet K., et al.
Publicado: (2019)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
por: Price, Maxwell Z., et al.
Publicado: (2023)

Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials
por: Singh, Alok, et al.
Publicado: (2022)

A Novel Assessment Tool for Impulsive Aggression in Children with Attention-Deficit/Hyperactivity Disorder
por: Ceresoli-Borroni, Gianpiera, et al.
Publicado: (2019)

New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
por: Yu, Chungping, et al.
Publicado: (2020)

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
por: Findling, Robert L., et al.
Publicado: (2021)

Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2023)

Early Motor Differences in Infants at Elevated Likelihood of Autism Spectrum Disorder and/or Attention Deficit Hyperactivity Disorder
por: Begum Ali, Jannath, et al.
Publicado: (2020)

Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment
por: Kosheleff, Alisa R., et al.
Publicado: (2023)

Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
por: Citrome, Leslie, et al.
Publicado: (2022)

Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
por: Citrome, Leslie, et al.
Publicado: (2022)

Behavioural and neural markers of tactile sensory processing in infants at elevated likelihood of autism spectrum disorder and/or attention deficit hyperactivity disorder
por: Piccardi, Elena Serena, et al.
Publicado: (2021)

Attention Deficit Hyperactivity Disorder in Medical Learners and Physicians and a Potentially Helpful Educational Tool
por: Im, David S, et al.
Publicado: (2023)

Relationships of attention-deficit hyperactivity disorder with defense styles and harm avoidance among male inpatients with alcohol use disorder
por: Evren, Cuneyt, et al.
Publicado: (2019)

Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients
por: Corbisiero, Salvatore, et al.
Publicado: (2017)

Attention deficit hyperactivity disorder in adults who present with self-harm: a comparative 6-month follow-up study
por: Olsson, Petter, et al.
Publicado: (2022)

Multiple Intelligences Profiles of Children with Attention Deficit and Hyperactivity Disorder in Comparison with Nonattention Deficit and Hyperactivity Disorder
por: Najafi, Mostafa, et al.
Publicado: (2017)

A strong dollar: help or harm?
por: Dollar, David, et al.
Publicado: (2020)

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia
por: Sumner, Calvin R, et al.
Publicado: (2009)

Management of attention-deficit hyperactivity disorder
por: Verma, Rohit, et al.
Publicado: (2011)

The history of attention deficit hyperactivity disorder
por: Lange, Klaus W., et al.
Publicado: (2010)

Stigma in attention deficit hyperactivity disorder
por: Mueller, Anna K., et al.
Publicado: (2012)

Attention Deficit Hyperactivity Disorder and Athletes
por: White, Russell D., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2dcomfsi89oln2liann8881sqb